Related Experiment Video
Updated: Aug 19, 2025
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
12.0K
Candesartan-the next anti-amyloid drug?
1Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Brain Communications
|November 28, 2022
Insights
Candesartan showed a favorable safety profile in non-hypertensive adults with early Alzheimer's disease. The study explored its effects on biomarkers, suggesting potential therapeutic avenues for prodromal Alzheimer's disease.
Area of Science:
- Neurology
- Pharmacology
- Biomarker Research
Background:
- Prodromal Alzheimer's disease (AD) presents challenges in early intervention.
- Identifying safe and effective treatments for individuals with cognitive decline is crucial.
- The role of angiotensin receptor blockers in neurodegenerative diseases is an emerging area of research.
Purpose of the Study:
- To evaluate the safety and tolerability of candesartan in non-hypertensive adults with prodromal Alzheimer's disease.
- To assess the effects of candesartan on key Alzheimer's disease biomarkers.
- To explore the potential of candesartan as a therapeutic agent in early-stage AD.
Main Methods:
- The commentary discusses a study involving non-hypertensive adults with prodromal AD.
- Safety assessments and biomarker analyses were central to the study's methodology.
- The study by Hajjar et al. is critically reviewed.
Main Results:
- Candesartan demonstrated a good safety profile in the studied population.
- The drug's impact on specific biomarkers related to Alzheimer's disease pathology was examined.
- Favorable effects on certain biomarkers were noted, warranting further investigation.
Conclusions:
- Candesartan appears to be a safe option for non-hypertensive individuals with prodromal AD.
- The observed biomarker changes suggest a potential disease-modifying effect.
- Further research is recommended to confirm these findings and explore clinical efficacy.
Abstract:
This scientific commentary refers to 'Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer's disease' by Hajjar et al. (https://doi.org/10.1093/braincomms/fcac270).
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
483
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
483
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
811
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
811
01:25Antihypertensive Drugs: Direct Renin Inhibitors
738
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
738
01:22Dose-Response Relationship: Potency and Efficacy
4.7K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.7K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
757
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
757
01:22Alzheimer's Disease: Treatment
241
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
241